Development and comparison of three 89Zr-labeled anti-CLDN18.2 antibodies to noninvasively evaluate CLDN18.2 expression in gastric cancer: a preclinical study.

Saved in:
Bibliographic Details
Title: Development and comparison of three 89Zr-labeled anti-CLDN18.2 antibodies to noninvasively evaluate CLDN18.2 expression in gastric cancer: a preclinical study.
Authors: Hu, Guilan1, Zhu, Wenjia1, Liu, Yu1, Wang, Yuan1, Zhang, Zheng1, Zhu, Shikun1, Duan, Wenwen2, Zhou, Peipei2, Fu, Chao1, Li, Fang1 lifang@pumch.cn, Huo, Li1 huoli@pumch.cn
Source: European Journal of Nuclear Medicine & Molecular Imaging. Jul2022, Vol. 49 Issue 8, p2634-2644. 11p. 1 Diagram, 1 Chart, 3 Graphs.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:16197070
DOI:10.1007/s00259-022-05739-3